Early-Life Cardiorespiratory Fitness and Long-term Risk of Prostate Cancer.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
09
04
2020
revised:
30
05
2020
accepted:
03
08
2020
pubmed:
29
8
2020
medline:
22
12
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
Adolescence is a period of rapid prostatic growth, yet is understudied for susceptibility for future risk of prostate cancer. We examined cardiorespiratory fitness (CRF) in late adolescence in relation to long-term prostate cancer risk. A population-based cohort study was conducted of all 699,125 Swedish military conscripts during 1972-1985 (97%-98% of 18-year-old men) in relation to risk of prostate cancer overall, aggressive prostate cancer, and prostate cancer mortality during 1998-2017 (ages 50-65 years). CRF was measured by maximal aerobic workload, and prostate cancer was ascertained using the National Prostate Cancer Register. Muscle strength was examined as a secondary predictor. In 38.8 million person-years of follow-up, 10,782 (1.5%) men were diagnosed with prostate cancer. Adjusting for sociodemographic factors, height, weight, and family history of prostate cancer, high CRF was associated with a slightly increased risk of any prostate cancer [highest vs. lowest quintile: incidence rate ratio (IRR), 1.10; 95% CI, 1.03-1.19; High CRF or muscle strength in late adolescence was associated with slightly increased future risk of prostate cancer, possibly related to increased screening, but neither with risk of aggressive prostate cancer nor prostate cancer mortality. These findings illustrate the importance of distinguishing aggressive from indolent prostate cancer and assessing for potential detection bias.
Sections du résumé
BACKGROUND
Adolescence is a period of rapid prostatic growth, yet is understudied for susceptibility for future risk of prostate cancer. We examined cardiorespiratory fitness (CRF) in late adolescence in relation to long-term prostate cancer risk.
METHODS
A population-based cohort study was conducted of all 699,125 Swedish military conscripts during 1972-1985 (97%-98% of 18-year-old men) in relation to risk of prostate cancer overall, aggressive prostate cancer, and prostate cancer mortality during 1998-2017 (ages 50-65 years). CRF was measured by maximal aerobic workload, and prostate cancer was ascertained using the National Prostate Cancer Register. Muscle strength was examined as a secondary predictor.
RESULTS
In 38.8 million person-years of follow-up, 10,782 (1.5%) men were diagnosed with prostate cancer. Adjusting for sociodemographic factors, height, weight, and family history of prostate cancer, high CRF was associated with a slightly increased risk of any prostate cancer [highest vs. lowest quintile: incidence rate ratio (IRR), 1.10; 95% CI, 1.03-1.19;
CONCLUSIONS
High CRF or muscle strength in late adolescence was associated with slightly increased future risk of prostate cancer, possibly related to increased screening, but neither with risk of aggressive prostate cancer nor prostate cancer mortality.
IMPACT
These findings illustrate the importance of distinguishing aggressive from indolent prostate cancer and assessing for potential detection bias.
Identifiants
pubmed: 32856610
pii: 1055-9965.EPI-20-0535
doi: 10.1158/1055-9965.EPI-20-0535
pmc: PMC7642066
mid: NIHMS1619370
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2187-2194Subventions
Organisme : NCI NIH HHS
ID : K07 CA143047
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Int J Obes (Lond). 2017 Feb;41(2):255-261
pubmed: 27867205
Cancer Res. 2016 Apr 15;76(8):2288-2300
pubmed: 26921328
Ann Oncol. 2018 May 1;29(5):1154-1179
pubmed: 29788165
Ann Oncol. 2020 Jan;31(1):103-114
pubmed: 31912782
Ann Intern Med. 2016 May 3;164(9):577-84
pubmed: 26954518
J Clin Lab Anal. 1996;10(6):468-9
pubmed: 8951622
Eur Urol. 2011 Nov;60(5):1029-44
pubmed: 21802197
Eur J Cancer Prev. 2007 Oct;16(5):415-21
pubmed: 17923812
Nat Rev Cancer. 2013 Mar;13(3):208-518
pubmed: 23363989
Int J Epidemiol. 2013 Aug;42(4):956-67
pubmed: 22561842
Scand J Med Sci Sports. 1995 Jun;5(3):143-6
pubmed: 7552756
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3252-61
pubmed: 18990768
Sports Med Open. 2019 Sep 3;5(1):39
pubmed: 31482208
J Urol. 1993 Aug;150(2 Pt 1):379-85
pubmed: 8326560
J Natl Compr Canc Netw. 2010 Feb;8(2):162-200
pubmed: 20141676
Ann Oncol. 2018 Feb 1;29(2):377-385
pubmed: 29161337
Prostate Cancer. 2011;2011:846263
pubmed: 22111000
Eur J Cancer. 2010 Jan;46(2):355-63
pubmed: 19683431
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Eur J Appl Physiol Occup Physiol. 1982;49(1):131-40
pubmed: 7201925
Heart. 2017 Nov;103(22):1780-1787
pubmed: 28500243
Int J Stroke. 2016 Aug;11(6):683-94
pubmed: 27016513
Cancer Epidemiol. 2011 Feb;35(1):59-65
pubmed: 20708996
BMC Med. 2017 Jul 13;15(1):115
pubmed: 28701188
Med Sci Sports Exerc. 2019 Dec;51(12):2474-2481
pubmed: 31730564
Natl Health Stat Report. 2010 Jun 25;(25):1-5
pubmed: 20939253
Prostate Cancer Prostatic Dis. 2015 Sep;18(3):197-207
pubmed: 25800589
Cancer. 2007 Feb 15;109(4):675-84
pubmed: 17211863
Br J Sports Med. 2011 May;45(6):504-10
pubmed: 20418526
Scand J Rehabil Med. 1969;1(3):139-42
pubmed: 5406735
Int J Obes (Lond). 2020 Jul;44(7):1546-1560
pubmed: 31974406
Curr Opin Clin Nutr Metab Care. 2004 May;7(3):271-7
pubmed: 15075918
JAMA Oncol. 2015 May;1(2):231-7
pubmed: 26181028
Cancer Res. 1999 Apr 1;59(7 Suppl):1765-1771s; discussion 1771s-1772s
pubmed: 10197594
Am J Med. 2004 Dec 15;117(12):912-8
pubmed: 15629729
J Urol. 1987 Jan;137(1):53-6
pubmed: 2432282
Med Sci Sports Exerc. 1996 Jan;28(1):97-104
pubmed: 8775361
PLoS One. 2013 Jul 05;8(7):e67579
pubmed: 23861774
Ann Oncol. 2012 Jul;23(7):1665-71
pubmed: 22228452
In Vivo. 1994 May-Jun;8(3):439-43
pubmed: 7803731
Int J Cancer. 2003 Jan 10;103(2):241-5
pubmed: 12455039
J Sleep Res. 2019 Dec;28(6):e12851
pubmed: 30957362
Evid Based Complement Alternat Med. 2011;2011:529053
pubmed: 19376839
Eur J Cancer. 2016 Dec;69:61-69
pubmed: 27816833
Ann Epidemiol. 2017 Jul;27(7):442-447
pubmed: 28789775
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BJU Int. 2005 May;95(7):961-2
pubmed: 15839913
Prostate Cancer Prostatic Dis. 2012 Jun;15(2):128-34
pubmed: 21986984
Am J Epidemiol. 2018 Mar 1;187(3):417-426
pubmed: 28641376
JAMA Intern Med. 2016 Feb;176(2):210-6
pubmed: 26784837
Ann Epidemiol. 2011 Apr;21(4):231-7
pubmed: 21376269
Am J Prev Med. 2017 Mar;52(3):353-361
pubmed: 27856116
Cancer Med. 2017 Apr;6(4):865-873
pubmed: 28317282
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):63-9
pubmed: 17179486
J Appl Physiol (1985). 2004 Feb;96(2):450-4
pubmed: 14715676
Int J Cancer. 2015 Oct 1;137(7):1749-57
pubmed: 25821151